Bank of America reaffirmed its “neutral” rating on shares of Cambridge-based Idenix Pharmaceuticals in a research note released Monday, according to Jags Report. The bank currently has a $7 price target, up from $6. Idenix announced a nonexclusive collaboration with Janssen Pharmaceuticals Inc. for “the clinical development of all-oral direct-acting antiviral HCV combination therapies” — in other words, drug combinations to treat infection with the hepatitis C virus.

BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.

Thanks & Welcome to Globe.com

You now have unlimited access for the next two weeks.

BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.